$0.02 EPS Expected for Ionis Pharmaceuticals Inc (IONS)

October 30, 2017 – By Adrian Mccoy

Investors wait Ionis Pharmaceuticals Inc (NASDAQ:IONS) to report on November, 8. its quarterly earnings Wall Street analysts expect $0.02 earnings per share, down $0.04 or 66.67 % from last year’s $0.06 same quarter earnings. This translates into $2.49 million profit for IONS giving the stock a 705.00 P/E. This is assuming the current $0.02 EPS is accurate. Ionis Pharmaceuticals Inc’s Wall Street analysts see -122.22 % EPS growth, taking into account the $-0.09 EPS reproted in the previous quarter, The stock increased 3.83% or $2.08 on October 27, reaching $56.4. About 1.48M shares traded. Ionis Pharmaceuticals Inc (NASDAQ:IONS) has risen 32.81% since October 30, 2016 and is uptrending. It has outperformed by 16.11% the S&P500.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Ratings Coverage

Among 4 analysts covering Ionis Pharmaceuticals Inc (NASDAQ:IONS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Ionis Pharmaceuticals Inc had 6 analyst reports since February 22, 2016 according to SRatingsIntel. The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) has “Buy” rating given on Tuesday, December 27 by Laidlaw. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, December 28 report. As per Friday, May 27, the company rating was maintained by Needham. On Friday, May 27 the stock rating was downgraded by BMO Capital Markets to “Market Perform”. The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) has “Mkt Perform” rating given on Tuesday, December 27 by Leerink Swann.

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid -targeted therapeutics. The company has market cap of $7.01 billion. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. It has a 268.44 P/E ratio. The Company’s divisions include Ionis Core and Akcea Therapeutics.

More notable recent Ionis Pharmaceuticals Inc (NASDAQ:IONS) news were published by: Streetinsider.com which released: “Ionis Pharma (IONS) Enters into Collaboration with Seventh Sense Biosystems” on October 18, 2017, also Prnewswire.com with their article: “Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to …” published on October 27, 2017, Fool.com published: “Why Ionis Pharmaceuticals Inc. Slipped This Morning” on October 24, 2017. More interesting news about Ionis Pharmaceuticals Inc (NASDAQ:IONS) were released by: Globenewswire.com and their article: “Akcea Therapeutics Named Among Top 100 Women-Led Businesses in Massachusetts …” published on October 27, 2017 as well as Prnewswire.com‘s news article titled: “Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients …” with publication date: October 13, 2017.